SEC Form 4
Filana Therapeutics, Inc. (FLNA) insider trading
In the 12 months to Oct 26, 2026, one FLNA insider reported open-market purchases of $356.3K across 2 filings; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $356.3K
- 2 filings · Richard Barry, President & CEO
Who traded FLNA, and when
- Purchase
FLNA daily close from Mar 11, 2026 to Oct 26, 2026, between $0.61 and $2.09, last $0.61. 0 sale and 2 purchase filings by 1 insider, marked at their filing dates. Richard Barry, President & CEO: bought $356.3K across 2 filings, first filed Sep 30, 2026, last Oct 1, 2026.
Largest mark · tap a row for others
Richard Barry · President & CEO
Filing 1 of 2 within a week · $356,328 total
Purchase $78,196
93,091 shares at $0.84 avg
Filed Sep 30, 2026 · traded Sep 28
Close on filing date $0.89
Richard Barry · President & CEO
President & CEO
$356.3K boughtOpen-market trades
2 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Richard Barry | President & CEO | — | $356.3K | 2 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Richard Barry President & CEO | Purchase | 306,813 | $0.91 | $278.1K | 1,337,964 | |
traded | Richard Barry President & CEO | Purchase | 93,091 | $0.84 | $78.2K | 1,031,151 |
GET /stocks/filings/vX/form-4?tickers=FLNA&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"FLNA"
],
"issuer_cik": "0001069530",
"owner_cik": "0001562371",
"accession_number": "0001437749-26-031654",
"form_type": "4",
"filing_date": "2026-10-01",
"period_of_report": "2026-09-29",
"issuer_name": "FILANA THERAPEUTICS, INC.",
"issuer_trading_symbol": "FLNA",
"owner_name": "Barry Richard",
"is_director": true,
"is_officer": true,
"officer_title": "President & CEO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-30",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 100000,
"transaction_price_per_share": 0.92,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 1337964,
"transaction_value": 92000,
"direct_or_indirect": "I",
"nature_of_ownership": "By Trust",
"footnotes": [
{
"id": "F2",
"description": "The purchase reported in column 4 is a weighted average price. The shares were purchased in multiple open market transactions at prices ranging from $0.91 to $0.93 per share. The reporting person undertakes to provide to Filana, any security holder of Filana or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth in this footnote."
}
]
},
{
"tickers": [
"FLNA"
],
"issuer_cik": "0001069530",
"owner_cik": "0001562371",
"accession_number": "0001437749-26-031654",
"form_type": "4",
"filing_date": "2026-10-01",
"period_of_report": "2026-09-29",
"issuer_name": "FILANA THERAPEUTICS, INC.",
"issuer_trading_symbol": "FLNA",
"owner_name": "Barry Richard",
"is_director": true,
"is_officer": true,
"officer_title": "President & CEO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-29",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 206813,
"transaction_price_per_share": 0.9,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 1237964,
"transaction_value": 186131.7,
"direct_or_indirect": "I",
"nature_of_ownership": "By Trust",
"footnotes": [
{
"id": "F1",
"description": "The purchase reported in column 4 is a weighted average price. The shares were purchased in multiple open market transactions at prices ranging from $0.86 to $0.94 per share. The reporting person undertakes to provide to Filana, any security holder of Filana or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each price within the range set forth in this footnote."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Filana Therapeutics, Inc.'s CEO sold stock?
No. Richard Barry (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is FLNA’s insider data?
These are FLNA Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track FLNA insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for FLNA every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.